Supriya Lifescience Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Supriya Lifescience Ltd trades at ₹867, in a confirmed uptrend and 9 weeks into that stage. That is +13.6% against its own 200-day average. It sits at 67% of a 52-week range of ₹577 to ₹1,009. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (3 weeks and counting).

Today the stock is in a confirmed uptrend — week 9 of stage 2, confirmed. At ₹867 it trades +13.6% versus its 200-day average and sits at 67% of its 52-week range (₹577–₹1,009).

Against the market, two honest reads. Cumulative: over the last 4.6 years the stock moved +79% while the NIFTY 500 moved +52% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (3 weeks and counting; last ahead the week of 2026-07-10) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Supriya Lifescience Ltd trades at 33.3× P/E, at the pricey end of its own range (85th percentile). Its long-run median P/E is 26.8×, measured across 4.6 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 33.3× is at the pricey end of its own range (85th percentile), against a long-run median of 26.8× measured over 4.6 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +11.3% against a +32.0% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 3y, of the +50.4%/yr price move, ~+32.6%/yr came from earnings growth and ~+17.8 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

Stage: Topping out Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Supriya Lifescience Ltd reads as topping out on its fundamental arc. Topping out — profit and EPS growth have decelerated hard (profit growth +56.4% at its peak → +11.2% latest) while ROCE still reads 24.3%. The read is built from 12 quarters across 4 curves, on full evidence.

Why it matters: decelerating from a peak is where good stories quietly end — the multiple usually notices late.

4-Factor Sector Score

63.8/100 — rank 8 of 24 in Pharma - API & CRAMS · 96% evidence confidence

Supriya Lifescience Ltd scores 63.8 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 8. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 16.2 + 19.5 + 15.5 + 12.6 = 63.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Supriya Lifescience Ltd reported ₹277 Cr of revenue in the Mar 26 quarter, +50.5% year on year. That is the 3rd straight quarter of year-on-year growth. Over 9 years it has compounded at 18.2% a year. The last full year, FY26, came in at ₹828 Cr. The last four reported quarters add to ₹828 Cr.

FY26 revenue came in at ₹828 Cr (+19.0% on the year), capping 9 years at 18.2% compound. The latest quarter (Mar 26) printed ₹277 Cr, +50.5% year on year — the 3rd consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +18.0% growth against the decade's 18.2% — the current year is running in line with its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +18.8% over the last 4 quarters against +20.5%/yr over the last 8 — stabilising; TTM profit +11.2% vs +32.0%/yr — rolling over.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Supriya Lifescience Ltd's operating margin is 35.0% in the Mar 26 quarter, −2.0 percentage points against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged 9.0% to 44.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 35.0%, −2.0 pp against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged 9.0%–44.0%.

🚨 Why the margin moved: operating margin went −1.4 pp year on year while gross margin went −8.3 pp — the loss came mostly from the gross line: input costs and pricing.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Supriya Lifescience Ltd earned ₹74.0 Cr of net profit in the Mar 26 quarter, +48.0% year on year. It is the 3rd consecutive quarter of growth. Full-year FY26 profit was ₹209 Cr. The 9-year compound rate is 48.4%. That is 26.7% of the quarter's revenue. The same quarter a year earlier earned ₹50.0 Cr.

Mar 26 profit was ₹74.0 Cr, +48.0% year on year — the 3rd consecutive quarter of growth. On the full year, FY26 printed ₹209 Cr (+11.2%), and the 9-year compound rate is 48.4%.

Why profit moved: revenue contributed +50.5% and the margin −2.0 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit +10.2% vs revenue +18.0%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 86% of Supriya Lifescience Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was ₹165 Cr of operating cash against ₹188 Cr of profit. After ₹162 Cr of capital spending, ₹3.0 Cr was left as free cash.

FY25: operating cash of ₹165 Cr against reported profit of ₹188 Cr, leaving free cash of ₹3.0 Cr after ₹162 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 86% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 86%: the cash cycle stretched 37 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.

Router verdict: the bigger cash user is investment — capital spending ran 7.2× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Supriya Lifescience Ltd's cash conversion cycle runs 167 days in FY26, up from 130 days in FY21. Capital spending ran ₹459 Cr over the last 3 years. At FY26 sales of ₹828 Cr each day of that cycle holds about ₹2.3 Cr, so roughly ₹379 Cr sits inside the business at any moment.

FY26: debtors at 97 days, inventory at 229 days — roughly 7.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 167 days, looser than FY21's 130.

The full loop: cash goes out to suppliers and production on day 0; stock waits 229 days to sell; customers pay about 97 days after that; and suppliers themselves are paid at 159 days — netting out to the 167-day cycle.

In money terms: at FY26 sales of ₹828 Cr, each day of the cycle holds about ₹2.3 Cr — so the 167-day loop keeps roughly ₹379 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹459 Cr over the last 3 fiscal years against ₹64.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹36.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Supriya Lifescience Ltd earns a ROCE of 25% in FY26. That is up from a trough of 14% in FY18. Return on invested capital clears the cost of that capital by +7.2 percentage points, so growth here adds value rather than only size. The wiring behind it is 25.2% net margin on 0.61× asset turns.

FY26 ROCE is 25%, recovered from a FY18 trough of 14% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 25.2% net margin × 0.61× asset turns × 1.13× balance-sheet leverage ≈ 17.4% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 19.2% − 12.0% = a +7.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Supriya Lifescience Ltd carries total debt of ₹5.0 Cr against shareholder equity of ₹1,198 Cr as of Mar 26, a debt-to-equity of 0.00 — effectively unlevered. On the annual view that ratio went from 0.04 in FY22 to 0.00 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹5.0 Cr against shareholder equity of ₹1,198 Cr — a debt-to-equity of 0.00. On the annual view, debt-to-equity went from 0.04 (FY22) to 0.00 (FY26). The returns on this page are earned, not borrowed.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Foreign institutions added 1.2 points of Supriya Lifescience Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 6.2% of the company. Domestic institutions moved −0.2 points over the same window, to 5.3%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Foreign institutions: +1.2 points over 8 quarters to 6.2%; Domestic institutions: −0.2 points over 8 quarters to 5.3%; Promoters: +0.0 points over 8 quarters to 68.3%.

Why the register moved: foreign institutions drove it (+1.2 points) — steady accumulation by institutions reading the same numbers this page reads.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Supriya Lifescience Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions